IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 69.51

Change

+1.12 (+1.64)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.07 (+0.72%)

USD 40.26B
FHLC Fidelity® MSCI Health Care In..

+0.47 (+0.67%)

USD 2.86B
FXH First Trust Health Care AlphaD..

+0.90 (+0.82%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.23 (-1.31%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.30 (+1.22%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.28 (+0.69%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

+0.53 (+0.55%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.22%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.00 (+1.52%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.12 (+0.40%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -62.51% 19% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.51% 19% F 7% C-
Trailing 12 Months  
Capital Gain -59.02% 19% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.02% 19% F 7% C-
Trailing 5 Years  
Capital Gain -52.03% 24% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.03% 24% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 4.90% 48% F 54% F
Dividend Return 6.25% 52% F 51% F
Total Return 1.35% 100% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 14.42% 71% C- 66% D+
Risk Adjusted Return 43.37% 67% D+ 61% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike